These findings demonstrate that targeting bacterial-derived DPP4 effectively mitigates intestinal fibrosis in CD, and that dual inhibition of both microbial and host DPP4 may yield even more pronounced therapeutic benefits. This evidence concerns the gene DPP4 and Cowden disease.